Why Nattokinase Dosage Matters More Than We Thought

THE UPSHOT

• This large human study reframes how we think about nattokinase. Meaningful improvements in atherosclerosis and lipid profiles were only seen at a higher, clinically effective dose of 10,800 FU per day, while commonly used lower doses showed little impact. 

• The findings reinforce a core longevity principle: dosage matters, context matters, and circulation (physical and energetic) is foundational to vitality. 

• Nattokinase does not act on blood sugar, making it relevant even for metabolically healthy individuals using CGMs. 

• When paired with movement, supportive nutrients, and an aligned lifestyle, improving vascular flow may be one of the most overlooked levers for long-term health, resilience, and coherence.

Longevity is about more than just adding more hours to life, it’s about enhancing the quality of those hours, and when we think of longevity, we think of flow. How is your blood moving through your veins? How is oxygen moving through your tissues? How is energy moving through the subtle body? 

A fascinating new clinical study gives us one of the most substantial human data sets we’ve ever had on nattokinase, a fermented-soy enzyme long appreciated in traditional diets and contemporary functional medicine for its cardiovascular actions (1).

The Study

Over 1,000 participants were observed for 12 months in this study, and the results were as clear as they were unexpected: nattokinase at 10,800 fibrinolytic units (FU) per day significantly slowed the progression of atherosclerosis, improved lipid profiles, and reduced carotid artery thickness and plaque size. Improvement rates across various lipid markers ranged from 66.5% to 95.4%. In contrast, a lower dose (3,600 FU/day) showed no significant benefit (2).

This matters because in much of the prior research and in common supplement use, we’ve long assumed a “baseline” dose of 2,000–4,000 FU/day is helpful. That dosage appears frequently in human trials looking at clot-related markers or blood pressure, and products standardized to ~2,000 FU per capsule are the most common on the market (3). But as the new study suggests, that level, while generally safe, may simply not be enough to drive meaningful changes in plaque regression and lipid metabolism for most adults aiming for cardiometabolic improvement.

Biological Implications

Nattokinase is a proteolytic enzyme originally discovered in natto, a fermented soybean food that has been part of the traditional Japanese diet for more than a thousand years. It acts on fibrin, the structural framework of blood clots, and supports the body’s natural fibrinolytic pathways (4). Over time, this can help the vascular system stay clear, reduce stagnation at the endothelial level, and encourage optimal blood flow. 

Lower doses seem to support fibrin turnover and some blood pressure markers, and when it comes to influencing lipid metabolism, vessel integrity, and plaque regression over the long term, the new research points to a higher threshold of enzymatic action. 

Dosage Considerations

Across human studies, nattokinase has been generally well tolerated, including at higher doses used in structured, long-term clinical settings, with no significant adverse events reported. Broader reviews of the research suggest that taking nattokinase at established dosages presents a low overall risk for hemorrhage when used appropriately (5).

That said, nattokinase’s fibrinolytic activity means it is not suitable for everyone. It can influence clot breakdown, so individuals with a history of deep vein thrombosis or known clotting disorders should avoid nattokinase, unless specifically advised by their healthcare provider. There is also a theoretical risk that an existing clot could dislodge and travel, leading to serious complications.

Caution is essential for anyone taking medications or supplements that affect blood clotting. This includes daily aspirin, prescription anticoagulants such as Eliquis, and blood-thinning supplements like turmeric or ginger. In these cases, nattokinase should only be considered under medical guidance, or avoided altogether.

As with all therapeutic supplements, nattokinase works best when it is dosed for the individual and in alignment with their overall health.

Wholistic Vascular Health 

And then there’s the lifestyle context. The high-dose group in the large atherosclerosis study saw even stronger effects if they exercised regularly, and synergistic benefit was seen with vitamin K2 and aspirin co-administration. This hints at how interconnected vascular health truly is, going beyond supplements, and encompassing the internal ecosystem of the body, the habits we cultivate, and the nutrients that support systemic coherence. 

CGMs for Real-time Insights

Some of my clients are already using continuous glucose monitors (CGMs) not because they have metabolic disease, but because they want real-time insight into their physiology. What nattokinase doesn’t do, according to this and other new clinical evidence, is meaningfully change blood glucose dynamics. A systematic review found no direct evidence for antidiabetic effects, and nattokinase hasn’t been shown to substantially alter glycemic markers in trials conducted so far (6).

So if, like some of my clients, your glucose curves are flat, stable, and in optimal range, nattokinase isn’t likely to make your CGM react the way a carbohydrate, stress shift, or workout might. Its primary actions are on vascular flow and fibrinolysis, not on insulin sensitivity or glucose clearance. That means you can use your CGM as a complementary biofeedback tool rather than an indicator of nattokinase’s effectiveness. Focus instead on your cholesterol panels, inflammatory markers, and subjective measures of circulatory ease. In other words: don’t expect glucose swings; expect flow improvements. This aligns with the biological role nattokinase targets.

Flow: Scientific and Energetic

From a longevity perspective, we often talk about mitochondria, telomeres, NAD+, and advanced glycation end products. If we think about the body as a river, nattokinase is one of the agents that helps keep that river clear, moving, and responsive to intention. Better flow on the physical level often translates to increased clarity, resilience, and a sense of lightness on the energetic level.

This is beyond metaphysical. It is grounded in physiology. Reduced plaque and improved lipid profiles mean fewer obstructions to delivery of oxygen and nutrients, less low-grade inflammation, and a nervous system that doesn’t feel chronically under siege.

This is an invitation to integrate ancient wisdom with modern evidence: support flow where it’s blocked, and watch how the whole system recalibrates.

As with all things, dosing and supplementation choices should be individualized, ideally with the guidance of a clinician familiar with your personal health landscape. But the emerging evidence about 10,800 FU/day is compelling enough to rethink what “baseline” really means when our goal is true, deep healing… not just maintenance.

xo – Serena

FAQs

Is nattokinase something to consider if my cholesterol is already “normal”?
A. Possibly. The study suggests nattokinase’s benefits extend beyond cholesterol numbers alone, influencing arterial thickness and plaque size. Even individuals with normal labs may carry subclinical plaque or endothelial stiffness that doesn’t yet show up on standard panels.

Does nattokinase replace lifestyle changes like diet and exercise?
A. No. In fact, the study showed that regular exercise enhanced nattokinase’s effects. It works best as a complement to movement, nourishment, and nervous system regulation, not as a substitute.

Why hasn’t this higher dose been widely recommended before?
A. Most earlier studies were smaller, shorter, or focused on clotting and blood pressure rather than plaque regression. The 10,800 FU dose hadn’t been tested at scale over a full year until recently, which is why this research is so influential.

Is nattokinase appropriate for people focused on longevity rather than disease reversal?
A. Yes, with context. Longevity isn’t only about preventing disease; it’s about preserving flow, elasticity, and efficient delivery of oxygen and nutrients. Vascular health is a quiet but critical pillar of healthy aging.

Can nattokinase affect energy levels or subjective vitality?
A. While not measured directly in the study, improved circulation can enhance oxygen delivery and reduce low-grade inflammation, which many people experience subjectively as greater clarity, stamina, or lightness over time.

Does nattokinase interact with fasting or plant-based diets?
A. There’s no evidence it interferes with fasting physiology or vegan nutrition patterns. Because it is derived from fermented soy, it fits well within plant-forward dietary frameworks often associated with longevity.

Should everyone take vitamin K2 or aspirin with nattokinase?
A. Not necessarily. While synergy was observed in the study, these additions should be individualized and discussed with a clinician, particularly for those with bleeding risk or on certain medications.

CITATIONS

1. Chen H, Chen J, Zhang F, Li Y, Wang R, Zheng Q, Zhang X, Zeng J, Xu F, Lin Y. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants. Front Cardiovasc Med. 2022 Aug 22;9:964977. doi: 10.3389/fcvm.2022.964977. Erratum in: Front Cardiovasc Med. 2022 Dec 05;9:1076420. doi: 10.3389/fcvm.2022.1076420. PMID: 36072877; PMCID: PMC9441630.
2. IBID.
3. Kim JY, Gum SN, Paik JK, et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res. 2008;31(8):1583-1588.18971533.
4. Chen H, McGowan EM, Ren N, Lal S, Nassif N, Shad-Kaneez F, Qu X, Lin Y. Nattokinase: A Promising Alternative in Prevention and Treatment of Cardiovascular Diseases. Biomark Insights. 2018 Jul 5;13:1177271918785130. doi: 10.1177/1177271918785130. PMID: 30013308; PMCID: PMC6043915.
5. Li X, Long J, Gao Q, Pan M, Wang J, Yang F, Zhang Y. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Rev Cardiovasc Med. 2023 Aug 15;24(8):234. doi: 10.31083/j.rcm2408234. PMID: 39076715; PMCID: PMC11266782.
6. Li X, Long J, Gao Q, Pan M, Wang J, Yang F, Zhang Y. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Rev Cardiovasc Med. 2023 Aug 15;24(8):234. doi: 10.31083/j.rcm2408234. PMID: 39076715; PMCID: PMC11266782.